Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN J ROSENBERG

Allopathic & Osteopathic Physicians Urology

NPI
1861488785
CMS profile
311678
Location
URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$327.28

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $327.28 13

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $157.73 5
AbbVie Inc. $79.65 3
Endo Pharmaceuticals Inc. $68.49 4
Merck Sharp & Dohme LLC $21.41 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN J ROSENBERG

NPI 1861488785 · CMS profile ID 311678

Allopathic & Osteopathic Physicians / Urology

URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861488785?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861488785?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861488785?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1861488785?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $327.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $21.1411/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998695259 CMS
Endo Pharmaceuticals Inc. $20.7410/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033383101 CMS
AbbVie Inc. $24.5210/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998695253 CMS
Boston Scientific Corporation $12.5509/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021976541 CMS
Endo Pharmaceuticals Inc. $18.3209/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033383089 CMS
Endo Pharmaceuticals Inc. $14.0705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033383073 CMS
AbbVie Inc. $33.9904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998695247 CMS
Boston Scientific Corporation $15.0704/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021962293 CMS
Boston Scientific Corporation $5.0203/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022352133 CMS
Boston Scientific Corporation $106.0003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022352137 CMS
Boston Scientific Corporation $19.0903/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022487951 CMS
Endo Pharmaceuticals Inc. $15.3602/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033383059 CMS
Merck Sharp & Dohme LLC $21.4101/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048375883 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $91.52 2
PY2020 $114.16 4
PY2021 $104.92 4
PY2022 $197.25 10
PY2023 $327.28 13
PY2024 $262.96 10
PY2025 $35.06 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,321.51 2
PY2023 Principal investigator $130,788.17 20
PY2022 Principal investigator $127,711.29 38
PY2021 Principal investigator $137,948.28 39
PY2020 Principal investigator $320,867.55 65
PY2019 Principal investigator $602,559.33 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $11,692.48 12/31/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 670126633
Principal investigator 1 Allergan Inc. $12,587.50 12/13/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 670110949
Principal investigator 1 Janssen Research & Development, LLC $2,302.20 12/05/2019 Non-covered Recipient Entity
The Ia Clnc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 654261481
Principal investigator 1 Dendreon Pharmaceuticals LLC $13,109.85 11/19/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756993
Principal investigator 1 Dendreon Pharmaceuticals LLC $609.50 11/19/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756995
Principal investigator 1 Dendreon Pharmaceuticals LLC $221.00 11/19/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756997
Principal investigator 1 Allergan Inc. $15,732.00 11/14/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 670098501
Principal investigator 1 Ipsen Innovation $250.00 11/14/2019 Non-covered Recipient Entity
COPERNICUS GROUP IRB
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis No dispute reported 06/30/2026 635346549
Principal investigator 1 Allergan Inc. $701.00 11/05/2019 Non-covered Recipient Entity
THE IOWA CLINIC P C
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670094427
Principal investigator 1 Allergan Inc. $4,142.00 10/18/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 670087821
Principal investigator 1 Astellas Pharma Global Development $27,598.00 10/17/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641403695
Principal investigator 1 Astellas Pharma Global Development $989.00 10/17/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641403769
Principal investigator 1 Astellas Pharma Global Development $11,552.00 09/26/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641403129
Principal investigator 1 Ipsen Innovation $16,755.05 09/19/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis No dispute reported 06/30/2026 635346547
Principal investigator 1 Allergan Inc. $56,111.75 09/18/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 670077001
Principal investigator 1 Dendreon Pharmaceuticals LLC $25,539.93 08/27/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756695
Principal investigator 1 Astellas Pharma Global Development $7,308.00 08/08/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641402288
Principal investigator 1 Astellas Pharma Global Development $6,930.00 08/08/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641402297
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,634.25 08/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756559
Principal investigator 1 Janssen Research & Development, LLC $2,241.00 08/06/2019 Non-covered Recipient Entity
The Ia Clnc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 654261479
Principal investigator 1 Allergan Inc. $12,359.50 07/09/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INCORPORATED
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670055595
Principal investigator 1 Janssen Research & Development, LLC $7,792.00 06/25/2019 Non-covered Recipient Entity
The Ia Clnc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 654261475
Principal investigator 1 PFIZER INC. $16,964.00 06/21/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671622133
Principal investigator 1 PFIZER INC. $78,504.22 06/21/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671622147
Principal investigator 1 Astellas Pharma Global Development $3,854.00 06/13/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641401001
Principal investigator 1 Astellas Pharma Global Development $50,373.00 06/13/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641401017
Principal investigator 1 Astellas Pharma Global Development $7,540.00 06/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641400899
Principal investigator 1 Allergan Inc. $14,544.50 06/04/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INCORPORATED
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670050015
Principal investigator 1 Janssen Research & Development, LLC $1,066.00 06/03/2019 Non-covered Recipient Entity
The Ia Clnc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 654261477
Principal investigator 1 Allergan Inc. $7,234.25 05/07/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INCORPORATED
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670043533
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $360.23 05/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629164987
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $360.23 05/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629165289
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $360.23 05/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629165587
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $360.23 05/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629165881
Principal investigator 1 Dendreon Pharmaceuticals LLC $16,309.80 04/30/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756379
Principal investigator 1 Allergan Inc. $356.00 04/09/2019 Non-covered Recipient Entity
THE IOWA CLINIC P C
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670036775
Principal investigator 1 Allergan Inc. $34,708.25 04/02/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INCORPORATED
A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVALUATING THE EFFICACY AND SAFETY OF BOTOX INTRAVESICAL INSTALLATION IN PARTICIPANTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE. No dispute reported 06/30/2026 670035395
Principal investigator 1 Dendreon Pharmaceuticals LLC $8,000.00 03/12/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER PROVENT No dispute reported 06/30/2026 703756227
Principal investigator 1 Ipsen Innovation $369.00 03/11/2019 Non-covered Recipient Entity
QUINTILES
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis No dispute reported 06/30/2026 635346471
Principal investigator 1 PFIZER INC. $617.50 03/11/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671619119
Principal investigator 1 Astellas Pharma Global Development $26,070.00 03/08/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641397907
Principal investigator 1 Astellas Pharma Global Development $45,153.00 03/08/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641397927
Principal investigator 1 Astellas Pharma Global Development $6,000.00 03/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641397560
Principal investigator 1 Astellas Pharma Global Development $1,200.00 03/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641397566
Principal investigator 1 Astellas Pharma Global Development $3,400.00 03/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641397573
Principal investigator 1 Astellas Pharma Global Development $1,800.00 03/06/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641397578
Principal investigator 1 PFIZER INC. $3,500.00 03/01/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671619117
Principal investigator 1 Janssen Research & Development, LLC $2,241.00 02/26/2019 Non-covered Recipient Entity
The Ia Clnc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 654261473
Principal investigator 1 Astellas Pharma Global Development $180.00 02/20/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641397111
Principal investigator 1 Astellas Pharma Global Development $11,778.00 02/14/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 641396943
Principal investigator 1 Ipsen Innovation $1,076.00 02/14/2019 Non-covered Recipient Entity
COPERNICUS GROUP IRB
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis No dispute reported 06/30/2026 635346371
Principal investigator 1 Ipsen Innovation $10,213.00 02/11/2019 Non-covered Recipient Entity
QUINTILES
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis No dispute reported 06/30/2026 635346449
Principal investigator 1 Astellas Pharma Global Development $180.00 02/04/2019 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER OAB SYMPTOMS WHILE TAKING THE ALPHA BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS LUTS DUE TO BENIGN PROSTATIC HYPERPLASIA BPH No dispute reported 06/30/2026 641396347
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 02/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629166457
Principal investigator 1 Ferring Pharmaceuticals AS $2,150.00 01/25/2019 Non-covered Recipient Entity
IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist No dispute reported 06/30/2026 655228737
Principal investigator 1 Ferring Pharmaceuticals AS $1,478.88 01/11/2019 Non-covered Recipient Entity
IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist No dispute reported 06/30/2026 655228725
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 01/01/2019 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 629166173